Mirati Therapeutics (MRTX) Prices 4.33M Share Common Offering at $202/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Pre-Open Stock Movers 10/27 (SPI) (XLNX) (HOG) Higher; (CATB) (DXCM) (CHGG) Lower (more...)
October 27, 2020 9:30 AM EDTToday's Pre-Open Stock Movers
Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) 63% LOWER; announced that the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD) did not meet the primary endpoint, which was a change from baseline in the North Star Ambulatory Assessment (NSAA) over one year of edasalonexent compared to placebo. The secondary endpoint timed function tests (time to stand, 10-meter walk/run and 4-stair climb) also did not show statistically significant improvements. Edasalonexent was observed to be generally safe and well-tolerated in this trial. Catabasis is stopping activities related to... More
After-Hours Movers 10/26: (LRN) (VRNS) (AIG) Higher; (CATB) (DXCM) (CHGG) Lower (more...)
October 26, 2020 6:01 PM EDTToday's After-Hours Stock Movers
Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) 63% LOWER; announced that the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD) did not meet the primary endpoint, which was a change from baseline in the North Star Ambulatory Assessment (NSAA) over one year of edasalonexent compared to placebo. The secondary endpoint timed function tests (time to stand, 10-meter walk/run and 4-stair climb) also did not show statistically significant improvements. Edasalonexent was observed to be generally safe and well-tolerated in this trial. Catabasis is stopping activities related to the... More
Mirati Therapeutics (MRTX) Announces $700M Proposed Public Offering of Common Stock
October 26, 2020 4:47 PM EDTMirati Therapeutics, Inc. (Nasdaq: MRTX) today announced that it intends to offer and sell in an underwritten public offering $700.0 million of shares of its common stock and a selling stockholder intends to offer 375,000 shares in the offering. In addition, Mirati and the selling... More
Mirati Therapeutics (MRTX) PT Raised to $198 at BofA Securities
October 26, 2020 9:12 AM EDTBofA Securities analyst Jason Gerberry raised the price target on Mirati Therapeutics (NASDAQ: MRTX) to $198.00 (from $183.00) while maintaining a Neutral rating.
... MoreMirati Therapeutics (MRTX) PT Raised to $210 at Piper Sandler
October 26, 2020 8:24 AM EDTPiper Sandler analyst Tyler Van Buren raised the price target on Mirati Therapeutics (NASDAQ: MRTX) to $210.00 (from $170.00) while maintaining an Overweight rating.
The analyst commented, "The adagrasib (formerly MRTX849) Phase Ib/II 45% ORR met investor expectations perour recent flash poll and appears improved versus... More
Mirati Therapeutics (MRTX) PT Raised to $225 at Oppenheimer
October 26, 2020 6:31 AM EDTOppenheimer analyst Jay Olson raised the price target on Mirati Therapeutics (NASDAQ: MRTX) to $225.00 (from $190.00) while maintaining an Outperform rating.
The analyst commented, "The triple meeting featured MRTX's adagrasib (formerly MRTX849) data in NSCLC and CRC from the KRYSTAL-1 clinical trial. In NSCLC,... More
